Life Sciences and Healthcare Leader ConcertAI Raises $150 Million Series C from at $1.9 Billion Valuation
Summary
In the past two years, ConcertAI has worked closely with leading biopharma innovators, medical societies, the US FDA, and healthcare providers to advance these solutions for an array of regulatory and post-approval studies. The company has made a deep commitment to ensuring the leading research is available at the community and regional health system level, in assurance of representativeness and access. “Bristol Myers Squibb is pleased to be one of the early partners of ConcertAI, utilizing their research data-as-a-service and software-as-a-service solutions deployed across multiple functions in our global enterprise,” said Vice President R&D Business Insights & Analytics Marisa Co, PhD. “Over the past two years, we’ve focused on novel clinical research solutions with the potential to accelerate the time from study initiation to regulatory decision, increasing our overall innovation capacity. Its vision and roadmap make it a leader in AI SaaS solutions for biomedical innovators and healthcare provider networks,” said Sixth Street Co-founding Partner Vijay Mohan.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
